On 19–20 October 2026, London-based Better Dairy announced that its precision-fermented lactopontin, a milk protein also called osteopontin, had achieved self-affirmed GRAS status in the United States. No agency has reviewed it. An independent expert panel the company assembled reviewed a dossier the company wrote, and concluded the ingredient is safe under its intended conditions of use. Green Queen reports that Better Dairy plans to notify FDA of the determination “next year”, which would be 2027. The company is launching the ingredient at SupplySide Global in Las Vegas on 28–30 October, and finished products are expected in the first quarter of 2027.

That sequence matters because of what is happening to the route in the middle. FDA’s proposed rule on GRAS, published on 11 August 2026, would make notification mandatory and end independent, un-notified conclusions for new uses. Comments close on 9 December 2026. This piece lays out what Better Dairy has actually disclosed, what the self-affirmed route does and does not give it, and one claim in the coverage, that this is the “only” lactopontin source in the US, that sits awkwardly with FDA’s own inventory.

What was announced, and where the sources differ

Five outlets covered the announcement within about 24 hours. They agree on the core and differ on emphasis.

Item What the coverage says Source
Status Self-affirmed GRAS in the US; “not FDA approval” Dairy News Today
Basis Safety dossier (composition, process, purity, specifications, safety); independent expert panel concluded safe under intended conditions FoodBev, Nutrition Insight
Scope Adult nutrition and supplements; infant formula not covered and under a separate pathway FoodNavigator
FDA notification Not required today; company plans to notify “next year” FoodNavigator, Green Queen
Launch Customer launches “in the coming months”; ingredient debuts at SupplySide Global, 28–30 October; finished products Q1 2027 Nutrition Insight, Green Queen
Production Proprietary food-grade yeast; 100,000-litre tanks secured via contract manufacturers in India and Europe Green Queen
Funding About £18m ($24m) raised to date, mostly on the casein programme; a new round is under way Green Queen
Claim “First commercially available supply of precision-fermented lactopontin” and “only commercially available source of lactopontin in the US” FoodBev

Two of these rows come from a single outlet. The 100,000-litre tank figure, the £18m funding figure and the “next year” notification timing all appear in Green Queen’s piece and in none of the other four we read. Treat them as single-source until Better Dairy publishes them itself. The other four outlets do not mention an FDA notification plan at all; FoodNavigator says only that companies are not currently required to notify.

What self-affirmed GRAS gives, and what it does not

Under the self-affirmed route a company reaches its own conclusion that a use is generally recognized as safe, usually with an expert panel, and markets the ingredient without sending FDA the basis. It is legal today. What it does not provide is a regulator’s reading of the dossier. Customers who want that comfort ask for a “no questions” letter, which is why, as FoodNavigator notes, many companies notify anyway.

Better Dairy’s own announcement language is careful. The Dairy News Today version quotes it as “a self-affirmed GRAS determination, not FDA approval.” The company’s stated plan to notify FDA in 2027 is consistent with that: the notice would be the step that turns a private conclusion into one FDA has reviewed and responded to.

The commercial gap is the point. If finished products reach shelves in the first quarter of 2027 and the notification is filed at some point “next year”, the first months of sales rest on the panel’s conclusion alone. Formulators who need a regulator’s letter before they will reformulate cannot get one from this announcement.

Practical consequence: if you are specifying lactopontin into a supplement or a nutrition product, ask the supplier for the expert panel’s report, the intended-use table it assessed, and a date for the FDA notice, and write the notification milestone into the supply agreement. A self-affirmed conclusion is a fair starting position. It is a weak one to carry through a retail listing review.

The proposed rule sits directly on this route

FDA’s proposal, published at 91 FR 51834 under Docket FDA-2025-N-3262, would convert the voluntary GRAS notification program into a mandatory one: firms would be required to notify FDA of the basis for their GRAS conclusion for a substance introduced into interstate commerce under the GRAS provision. The proposal describes independent, un-notified conclusions as something that would no longer be available for new uses once the rule takes effect, and it includes a time-limited streamlined option for certain uses of substances already in interstate commerce before the effective date. Comments are due on 9 December 2026.

We analysed the proposal’s structure in our earlier piece on the self-affirmed route and the one-year window. We did not re-verify the proposal’s effective-date mechanics for this article, and the final rule’s effective date does not yet exist. Two things follow from what we did verify.

First, Better Dairy’s timing is not accidental. A product that is already in commerce before the effective date is, on the proposal’s own description, the kind of substance the streamlined option addresses. Green Queen reports that the company’s notification plan is unchanged by the proposal. Whether a 2027 filing would fall inside any window depends on a date that has not been set.

Second, the dependence on that date makes this a regulatory-sequencing bet rather than a shortcut. Self-affirming first lets the company sell before an agency review; the cost is that it is selling into a rule change whose final form it cannot see.

“The only source in the US”: what FDA’s inventory shows

FoodBev reports Better Dairy’s claim that this is the first commercially available supply of precision-fermented lactopontin, which may well be true, and also the “only commercially available source of lactopontin in the US.” Green Queen carries a similar claim. The second claim is broader, and the public record is not clean on it.

FDA’s GRAS inventory, last updated on 15 September 2026, returns one record for osteopontin: GRN 716, bovine milk osteopontin. The notifier’s submission shows it was filed by Arla Foods Ingredients in July 2017 for Lacprodan OPN-10, a whey-derived ingredient with at least 78% protein, of which osteopontin is at least 95%, intended for term infant formula and powdered beverages for children aged one to three. The inventory entry reads that FDA ceased to evaluate the notice at the notifier’s request, and the closure is dated 1 February 2018. The FDA letter records that the agency had “questions regarding the intended use of bOPN in infant formulas.”

Three points from that record. First, it is not a clearance: nothing in it is a “no questions” letter. Second, it concerned infant formula, which Better Dairy’s current determination explicitly excludes. Third, Arla did obtain a positive EFSA opinion in 2022 on bovine milk osteopontin for infant formula, follow-on formula and ready-to-eat dairy meals for children, as Arla’s own release records, with a maximum assessed concentration of 151 mg per litre reported in trade coverage of that opinion, so a bovine-derived osteopontin ingredient exists as a commercial product in at least one market.

What we cannot say is whether Arla’s ingredient is sold in the United States today. A GRAS notice is not required to sell, and the absence of a “no questions” letter in the inventory does not establish absence from the market. So the honest reading is narrow: the claim is probably defensible if “lactopontin” means a standalone, adult-nutrition ingredient, and it is unverifiable if it means any osteopontin available to US manufacturers. The coverage does not define the term.

Practical consequence: when a supplier calls itself the “only” source, ask which comparison set it means. Here the answer changes depending on whether infant-formula ingredients count.

Scale: what the numbers do and do not imply

Green Queen cites about 18 mg of lactopontin per litre of dairy, and says conventional extraction would need tens of thousands of litres of milk to yield a kilogram. That is arithmetically consistent: at 18 mg per litre, one kilogram corresponds to roughly 55,600 litres of milk, before any extraction loss. That figure is our calculation from the reported concentration, not a number Better Dairy published.

Against that, the reported 100,000-litre fermentation tanks sound large, but a tank volume says nothing about output without a titre, the grams of protein per litre of broth, which no source gives. The same applies to price: Green Queen reports that no price is given and that the CEO points to “cost-in-use”, arguing that low inclusion levels let the ingredient fit most existing price points. No use level appears in any of the five articles.

The dependence on contract manufacturers in India and Europe is the more instructive detail. It is the capacity-access pattern we have traced elsewhere, for example in the Daisy Lab and Mycofeast arrangement: the ingredient company holds the process and the regulatory file, and someone else’s tanks hold the volume. Whether those tanks have been used for a Better Dairy run, or only secured for “upcoming production campaigns”, is not specified.

The counter-argument

The case for treating this as unremarkable is strong. Self-affirmed GRAS has been the dominant route for new food ingredients for years, the company says it will notify, and it has said what the determination does not cover. The ingredient is for adult supplements, a lower-scrutiny use than infant formula. A rule that is still a proposal, with comments open until December, binds nobody today. A company that waits for every proposal to finalise before launching would never launch.

There is also a fair reading in which the plan is good practice: file the notice with real market experience and a finalised use-level table behind it. The weakness is only that none of the five outlets says what the use levels are, so no reader can yet judge whether the panel assessed the same exposure the product will deliver.

What we could not establish

  • Use levels and intended-use table. None of the five articles gives them.
  • The expert panel’s membership and report. Not published in any source we read.
  • Whether Arla’s Lacprodan OPN-10 is on sale in the US. FDA’s inventory shows only a closed, un-cleared notice.
  • Which part of the Green Queen details are confirmed by the company in writing. The 100,000-litre tanks, £18m funding and 2027 notification timing appear in one outlet.
  • Whether lactopontin production has run at commercial scale, and at what titre or cost.
  • The effective date and final shape of FDA’s rule, and so whether a 2027 notice would fall inside any transition window.
  • Whether the “Q1 2027” finished-product timing and “coming months” ingredient launch refer to the same events. The outlets word them differently.

What to watch

  1. An FDA notice from Better Dairy, and its GRN number, against the “next year” statement.
  2. Use levels in the first named customer’s product, which will be the first public intake figure.
  3. The final rule and how it treats substances already in commerce.
  4. Any clarification of the “only source in the US” wording once the SupplySide launch materials are public.
  5. Whether infant-nutrition work ever reaches an FDA filing, given the 2018 closure of the one bovine osteopontin notice.